$0.81
4.33% yesterday
Nasdaq, May 20, 10:14 pm CET
ISIN
US00534A1025
Symbol
IVVD

Adagio Therapeutics Inc Stock price

$0.81
+0.25 44.24% 1M
+0.04 5.35% 6M
+0.37 82.62% YTD
-1.44 64.04% 1Y
-2.14 72.57% 3Y
-16.19 95.24% 5Y
-16.19 95.24% 10Y
Nasdaq, Closing price Tue, May 20 2025
+0.03 4.33%
ISIN
US00534A1025
Symbol
IVVD
Sector
Industry

Key metrics

Market capitalization $97.07m
Enterprise Value $49.88m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 1.36
P/S ratio (TTM) P/S ratio 2.65
P/B ratio (TTM) P/B ratio 1.79
Revenue (TTM) Revenue $36.69m
EBIT (operating result TTM) EBIT $-147.71m
Free Cash Flow (TTM) Free Cash Flow $-141.55m
Cash position $48.08m
EPS (TTM) EPS $-1.19
P/E forward 12.78
P/S forward 0.58
EV/Sales forward 0.30
Short interest 10.62%
Show more

Is Adagio Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,789 stocks worldwide.

Adagio Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

3 Analysts have issued a Adagio Therapeutics Inc forecast:

2x Buy
67%
1x Hold
33%

Analyst Opinions

3 Analysts have issued a Adagio Therapeutics Inc forecast:

Buy
67%
Hold
33%

Financial data from Adagio Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
37 37
-
100%
- Direct Costs 5.78 5.78
182% 182%
16%
31 31
1,608% 1,608%
84%
- Selling and Administrative Expenses 59 59
20% 20%
160%
- Research and Development Expense 117 117
28% 28%
318%
-144 -144
32% 32%
-394%
- Depreciation and Amortization 3.33 3.33
62% 62%
9%
EBIT (Operating Income) EBIT -148 -148
32% 32%
-403%
Net Profit -143 -143
31% 31%
-389%

In millions USD.

Don't miss a Thing! We will send you all news about Adagio Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Adagio Therapeutics Inc Stock News

Neutral
Seeking Alpha
6 days ago
Invivyd, Inc. (NASDAQ:IVVD ) Q1 2025 Earnings Conference Call May 15, 2025 8:30 AM ET Company Participants Katie Falzone - Senior Vice President, Finance Marc Elia - Chairman Tim Lee - Chief Commercial Officer Bill Duke - Chief Financial Officer Dr. Robert Allen - Chief Scientific Officer Dr. Mark Wingertzahn - Senior Vice President, Clinical Development Conference Call Participants Kyle Yang -...
Neutral
GlobeNewsWire
6 days ago
WALTHAM, Mass., May 15, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced financial results for the quarter ended March 31, 2025, and provided recent business highlights.
Neutral
GlobeNewsWire
7 days ago
WALTHAM, Mass., May 14, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced it has submitted a Citizen Petition with the U.S. Food and Drug Administration (FDA) calling on the Agency to evolve from historical approaches to the development of vaccines and monoclonal antibodies (mAbs) for COVID-19 prevention, in order to rebuild American's trust in scientific data, public health...
More Adagio Therapeutics Inc News

Company Profile

Adagio Therapeutics, Inc. engages in the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The firm develops antibodies that can neutralize SARS-CoV-2, SARS-CoV-1, and additional emergent coronaviruses. It offers, ADG20, a monoclonal antibody targeting the spike protein of SARS-CoV-2 and related coronaviruses. The company was founded by Tillman U. Gerngross, Ren? Russo and Laura Walker on June 3, 2020 and is headquartered in Waltham, MA.

Head office United States
CEO William Duke
Employees 99
Founded 2020
Website invivyd.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today